ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0569

Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus

Risa Wakiya1, Hiromi Shimada1, Shusaku Nakashima1, Taichi Miyagi2, Yusuke Ushio3, Koichi Sugihara4, Mao Mizusaki1, Rina Mino5, Kanako Chujo6, Ryoko Kagawa3, Hayamasa Yamaguchi3, Tomohiro Kameda1 and Hiroaki Dobashi1, 1Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, 3Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, 4Kagawa University, Miki-cho, Kita-gun, Japan, 5Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 6Kagawa University, Miki, Kita District, Kagawa, Japan

Meeting: ACR Convergence 2023

Keywords: Biomarkers, immunology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: S100, a damage-related molecular pattern factor, was reported to be a biomarker associated with disease activity in SLE. Additional hydroxychloroquine, which could regulate IFN signature, was found to modulate serum S100 in patients with SLE. However, what SLE pathophysiology S100 reflects remains unclear. The study aimed to determine the usefulness of S100 as a biomarker of SLE pathogenesis.

Methods: This single-center, retrospective, observational study enrolled patients with SLE admitted to our hospital between January 2016 and December 2021. The SELENA-SLEDAI, SLE-DAS, and lupus low disease activity state scale were used to measure disease activity. Serum cytokines reported to associated with SLE activity (TNF-α, IL-8, monocyte chemoattractant protein-1, IL-1ra) were measured by multiplex Luminex assay, and serum S100A8 and S100A9 by ELISA. The correlation between these biomarkers and organ involvements was analyzed.

Results: Overall, 120 patients (9 men and 111 women; mean age, 40.5 years) were included. Table 1 shows the patient’s characteristics when measuring serum S100A8, S100A9, and cytokines. The level of TNF-α, IL-8, monocyte chemoattractant protein-1, and IL-1ra were not associated with type of organ involvements. Renal involvement was related to the level of S100 A8 and A9 (Figure 1). S100A8 and A9 levels correlated with leukocyte and neutrophil counts positively and were significantly lower in patients with leukopenia (Figure 1). The SLEDAI score showed a slightly negative correlation with S100A8 levels, but not with S100A9 levels, whereas S100A9 levels showed a slightly positive correlation with the CLASI activity score (r = 0.19, P = 0.039). S100A8 levels positively correlated with IL-1ra levels (r = 0.19, P = 0.039) and S100A9 with IL-8 and IL-1ra levels (IL-8; r = 0.30, P = 0.022 and r = 0.53, P < 0.0001). Regarding SLEDAI scores of 1–4 (n = 54), patients with higher S100A8 and S100A9 levels tended to have higher SLE-DAS scores. S100A8 and S100A9 levels were higher in patients with cutaneous lesions, which correlated with the CLASI activity score (S100A8, r = 0.27, P = 0.047; S100A9, r = 0.29, P = 0.033; Figure 2).

Conclusion: Serum TNF-α, IL-8, monocyte chemoattractant protein-1, and IL-1ra were not associated with organ lesions. However, S100 was significantly associated with renal and skin lesions, which are strongly suggested to be associated with IFN.

Supporting image 1

Table 1. Characteristics of patients with SLE enrolled in this study
#Nonparametric distributions are represented as median (interquartile range [IQR]).

Supporting image 2

Figure 1. Association of serum S100 protein levels with lupus nephritis, immunological biomarkers, and leukopenia
P-values were determined using the Mann–Whitney U test or Pearson’s correlation coefficient (r).

Supporting image 3

Figure 2. Association of serum S100 protein levels with cutaneous lesions in patients with SLEDAI scores of 1–4 (n = 54)
For statistical analysis, the Mann–Whitney U test was used for the presence of lesions, and Pearson’s correlation coefficient (r) was used for the association with CLASI activity.


Disclosures: R. Wakiya: None; H. Shimada: None; S. Nakashima: None; T. Miyagi: None; Y. Ushio: None; K. Sugihara: None; M. Mizusaki: None; R. Mino: None; K. Chujo: None; R. Kagawa: None; H. Yamaguchi: None; T. Kameda: None; H. Dobashi: None.

To cite this abstract in AMA style:

Wakiya R, Shimada H, Nakashima S, Miyagi T, Ushio Y, Sugihara K, Mizusaki M, Mino R, Chujo K, Kagawa R, Yamaguchi H, Kameda T, Dobashi H. Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/serum-s100a8-and-s100a9-are-useful-biomarker-indicated-ifn-associated-organ-involvements-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-s100a8-and-s100a9-are-useful-biomarker-indicated-ifn-associated-organ-involvements-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology